Company intelligence / Profile preview
CanariaBio
Seoul, South Koreacanariabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CanariaBio has completed enrollment for a Phase II ovarian cancer trial as of August 2024. Their lead product oregovomab is in Phase III trials for ovarian cancer treatment across 163 sites in 16 countries. The company is also developing other immunotherapies for cancer indications with high unmet medical needs.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesImmunotherapiesSmall molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Hikma
Beyond the preview
Go deeper on CanariaBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CanariaBio.